Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant

Aprepitant, a selective high-affinity antagonist of human substance P/neurokinin 1 (NK(1)) receptors, is the active ingredient of EMEND(®) which has recently been approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant undergoes extensive metabolism, pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Olver, Ian, Shelukar, Suhas, Thompson, Karen C
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673828/
https://www.ncbi.nlm.nih.gov/pubmed/17722507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673828/
https://www.ncbi.nlm.nih.gov/pubmed/17722507

Ejemplares similares